A Case of Angioid Streaks in Congenital Dyserythropoietic Anaemia Type II

The authors describe a case report of retinal angioid streaks (AS) in a patient with congenital dyserythropoietic anaemia (CDA) type II and compare the retinal findings to those of an affected first-degree relative without ocular manifestations of the disease. A 52-year-old man with a confirmed diagnosis of CDA type II has been dependent on treatment with regular transfusions and chelating agents. He presents with bilateral retinal AS. The subject’s brother, who also has CDA type II, underwent splenectomy in childhood, and has required no treatment since then. He has no ocular manifestations of the disease. To the authors’ knowledge, this is only the second time that the presence of retinal AS has been reported in a case of CDA type II. It has been reported more frequently with CDA types I and III. The milder course of disease in the subject’s brother likely accounts for the differing retinal findings. The authors explore the pathophysiology of AS in this disease, and the differential diagnosis of chelating agent toxicity. Diagnostic uncertainty around retinal findings can lead to withholding of essential systemic treatment and inappropriate ophthalmological follow-up. It is recommended that all patients with CDA undergo eye examinations.

From initial treatment design to final disposal of chelating agents: a review of corrosion and degradation mechanisms

In this review, we discuss how chelating agents and their products can cause corrosion and how it goes through the oilfield cycle including thermal, photo, and biodegradation.

Metal Complexes or Chelators with ROS Regulation Capacity: Promising Candidates for Cancer Treatment

Reactive oxygen species (ROS) are rapidly eliminated and reproduced in organisms, and they always play important roles in various biological functions and abnormal pathological processes. Evaluated ROS have frequently been observed in various cancers to activate multiple pro-tumorigenic signaling pathways and induce the survival and proliferation of cancer cells. Hydrogen peroxide (H2O2) and superoxide anion (O2•−) are the most important redox signaling agents in cancer cells, the homeostasis of which is maintained by dozens of growth factors, cytokines, and antioxidant enzymes. Therefore, antioxidant enzymes tend to have higher activity levels to maintain the homeostasis of ROS in cancer cells. Effective intervention in the ROS homeostasis of cancer cells by chelating agents or metal complexes has already developed into an important anti-cancer strategy. We can inhibit the activity of antioxidant enzymes using chelators or metal complexes; on the other hand, we can also use metal complexes to directly regulate the level of ROS in cancer cells via mitochondria. In this review, metal complexes or chelators with ROS regulation capacity and with anti-cancer applications are collectively and comprehensively analyzed, which is beneficial for the development of the next generation of inorganic anti-cancer drugs based on ROS regulation. We expect that this review will provide a new perspective to develop novel inorganic reagents for killing cancer cells and, further, as candidates or clinical drugs.

Reusing Flowback and Produced Water with Different Salinity to Prepare Guar Fracturing Fluid

Economical and environmental concerns have forced the oil and gas industry to consider reusing flowback and produced water for fracturing operations. The major challenge is that the high-salinity of flowback water usually prevents its compatibility with several fracturing fluid additives. In this paper, the authors explored an economic and effective method to prepare guar fracturing fluids with different salinity waters. The main research idea was to use chelating agents to mask metal ions, such as calcium and magnesium, that are harmful to crosslinking. Firstly, a complexometric titration test was conducted to measure the chelating ability of three chelating agents. Secondly, through viscosity, crosslinking, and hanging tests, it was verified that the complex masking method could cope with the problem of high-valence metal ions affecting crosslinking. Thirdly, the preferred chelating agent was mixed with several other additives, including thickeners, crosslinkers, and pH regulators, to prepare the novel guar fracturing fluid. The comprehensive performances of the novel fluid system were tested such as temperature and shear resistance, friction reduction, gel-breaking performance, and core damage rate. The results show that the organophosphate chelating agent (i.e., CA-5) had the greatest ability to chelate calcium and magnesium ions. There was a good linear relationship between the dosage of CA-5 and the total molar concentration of calcium and magnesium ions in brine water. The main mechanism was that the chelating agent formed a complex with calcium and magnesium ions at a chelation ratio of 1:5. The test results of the comprehensive performance evaluation indicate that the prepared guar fracturing fluid met the requirements for field application, and the lower the salinity of the flowback water, the more it is economical and effective.

Attention deficit hyperactivity disorder (ADHD)

The objective of this study, stated as Previous Notation, is to demonstrate that Attention Deficit Hyperactivity Disorder Pathology presents a differentiated condition in carriers where a significant percentage, close to 60%, present a higher level of zinc elimination by kidneys. In this study, a direct relation of Zinc Mettalicum pathogenetic symptoms, this disturbance and the elimination of this element which participates in neurotransmission process were identified, and the relation with elements from regular diet, which can act as zinc chelating agents would be involved in the evolution of this disturbance, justifying the issue of individual susceptibility, essential in homeopathic investigation

Side-by-Side Comparison of Five Chelators for 89Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability

In this work, five different chelating agents, namely DFO, CTH-36, DFO*, 3,4,3-(LI-1,2-HOPO) and DOTA-GA, were compared with regard to the relative kinetic inertness of their corresponding 89Zr complexes to evaluate their potential for in vivo application and stable 89Zr complexation. The chelators were identically functionalized with tetrazines, enabling a fully comparable, efficient, chemoselective and biorthogonal conjugation chemistry for the modification of any complementarily derivatized biomolecules of interest. A small model peptide of clinical relevance (TCO-c(RGDfK)) was derivatized via iEDDA click reaction with the developed chelating agents (TCO = trans-cyclooctene and iEDDA = inverse electron demand Diels-Alder). The bioconjugates were labeled with 89Zr4+, and their radiochemical properties (labeling conditions and efficiency), logD(7.4), as well as the relative kinetic inertness of the formed complexes, were compared. Furthermore, density functional theory (DFT) calculations were conducted to identify potential influences of chelator modification on complex formation and geometry. The results of the DFT studies showed—apart from the DOTA-GA derivative—no significant influence of chelator backbone functionalization or the conjugation of the chelator tetrazines by iEDDA. All tetrazines could be efficiently introduced into c(RGDfK), demonstrating the high suitability of the agents for efficient and chemoselective bioconjugation. The DFO-, CTH-36- and DFO*-modified c(RGDfK) peptides showed a high radiolabeling efficiency under mild reaction conditions and complete 89Zr incorporation within 1 h, yielding the 89Zr-labeled analogs as homogenous products. In contrast, 3,4,3-(LI-1,2-HOPO)-c(RGDfK) required considerably prolonged reaction times of 5 h for complete radiometal incorporation and yielded several different 89Zr-labeled species. The labeling of the DOTA-GA-modified peptide was not successful at all. Compared to [89Zr]Zr-DFO-, [89Zr]Zr-CTH-36- and [89Zr]Zr-DFO*-c(RGDfK), the corresponding [89Zr]Zr-3,4,3-(LI-1,2-HOPO) peptide showed a strongly increased lipophilicity. Finally, the relative stability of the 89Zr complexes against the EDTA challenge was investigated. The [89Zr]Zr-DFO complex showed—as expected—a low kinetic inertness. Unexpectedly, also, the [89Zr]Zr-CTH-36 complex demonstrated a high susceptibility against the challenge, limiting the usefulness of CTH-36 for stable 89Zr complexation. Only the [89Zr]Zr-DFO* and the [89Zr]Zr-3,4,3-(LI-1,2-HOPO) complexes demonstrated a high inertness, qualifying them for further comparative in vivo investigation to determine the most appropriate alternative to DFO for clinical application.

Optimizing Seawater Based Fracture Fluids Rheology Utilizing Chelating Agents

Due to the scarcity and high cost of freshwater, especially in the Gulf region, utilization of seawater as a fracturing fluid gained noticeable interest. However, seawater contains high total dissolved solids (TDS) that may damage the formation and degrade the performance of the fracturing fluids. Numerous additives are required to reduce the damaging effect and improve the viscosity resulting in an expensive and non-eco-friendly fracturing fluid system. Chelating agents, which are environmentally benign, are proposed in this study as the replacement of many additives for seawater fracturing fluids. This study focuses on optimizing chelating agents to achieve high viscosity employing the standard industry rheometers. Carboxymethyl Hydroxypropyl Guar Gum (CMHPG) polymer, which is effective in hydraulic fracturing, was used in this research with 0.5 and 1.0 wt% in deionized water (DW) as well as seawater (SW). It was first tested as a standalone additive at different conditions to provide a benchmark then combined with different concentrations, and pH level chelating agents. In this study the hydration test was conducted through different conditions. It was observed that CMHPG, when tested as a standalone additive, provided slightly higher viscosity in SW compared to DW. Also, increasing polymer concentration from 0.5 to 1.0 wt% provided three folds of viscosity. The viscosity did not show time dependence behavior at room temperature for the aforementioned experiments where all hydration tests were run at 511 1/s shear rate. Temperature, however, had a significant impact on both viscosity magnitude and behavior. At 70 °C, the fluid viscosity increased with time where low viscosity was achieved early on but kept increasing with shearing time. Similarly, high pH chelating agents provided time dependant viscosity behavior when mixed with CMHPG. This behavior is important as low viscosity is favorable during pumping but high viscosity when the fluids hit the formation. The study investigates the possibility of utilizing chelating agents with seawater to replace numerous additives. It acts as a crosslinker at early shearing times, where a gradual increase in viscosity was observed and a breaker in the reservoir harsh conditions. It also captures the divalent ions that are common in seawater, which replaces the need for scale inhibitors. The viscosity increase behavior can be controlled by adjusting the pH level, which could be desirable during operations.

MOLECULAR DOCKING AND ADMET PREDICTION OF 5-BENZYLOXYTRYPTOPHAN AS A POTENTIAL RADIOPHARMACEUTICAL KIT FOR MOLECULAR IMAGING OF CANCER

Objective: This in silico study aims to determine the inhibition effect of 5-BOTP with various bifunctional chelating agents (BFCA); NOTA, DOTA, TETA, CTPA, H2CB-DO2A, H2CBTE2A against the antiporter site of the LAT1. Methods: The research method consisted of the binding mode of 5-BOTP and its derivatives with LAT1, the docking score, the analysis of preADMET, and the overview of Ro5 compatibility. Results: The results showed that 5-BOTP-NOTA and 5-BOTP-DOTA had interactions with the gating residue (Phe252, Trp257, Asn258, and Tyr259) on the antiporter site of LAT1. 5-BOTP-NOTA and 5-BOTP-DOTA affinity are around-11.50 and-9.14 kcal/mol, respectively. Conclusion: Based on this study, 5-BOTP-NOTA and 5-BOTP-DOTA are the new compounds that have the potential as a theranostic agent of cancer by inhibiting LAT1.